Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
Background: Few data exist on how ofatumumab treatment impacts SARS-CoV-2 booster vaccination response. Methods: KYRIOS is an ongoing prospective open-label multicenter study on the response to initial and booster SARS-CoV-2 mRNA vaccination before or during ofatumumab treatment in relapsing MS patients. The results on the initial vaccination cohort have been published previously. Here, we describe 23 patients who received their initial vaccination outside of the study but booster vaccination during the study. Additionally, we report the booster results of two patients in the initial vaccination cohort. The primary endpoint was SARS-CoV-2-specific T-cell response at month 1. Furthermore, serum total and neutralizing antibodies were measured. Results: The primary endpoint was reached by 87.5% of patients with booster before (booster cohort 1, N = 8) and 46.7% of patients with booster during ofatumumab treatment (booster cohort 2, N = 15). Seroconversion rates for neutralizing antibodies increased from 87.5% at baseline to 100.0% at month 1 in booster cohort 1 and from 71.4% to 93.3% in booster cohort 2. Of note, 3 of 4 initially seronegative patients in booster cohort 2 and one seronegative patient in the initial vaccination cohort seroconverted after the booster during ofatumumab treatment. Conclusions: Booster vaccinations increase neutralizing antibody titers in ofatumumab-treated patients. A booster is recommended in ofatumumab-treated patients.
Details
Original language | English |
---|---|
Article number | 978 |
Pages (from-to) | 1-12 |
Number of pages | 12 |
Journal | Vaccines : open access journal |
Volume | 11 |
Issue number | 5 |
Early online date | 13 May 2023 |
Publication status | Published - May 2023 |
Peer-reviewed | Yes |
External IDs
Scopus | 85160295122 |
---|---|
Mendeley | bee81f00-6a6c-3b0f-9aa1-f4599486061b |
Keywords
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- COVID-19 vaccination, T-cell responses, neutralizing antibodies, ofatumumab, relapsing multiple sclerosis